{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:43:33Z","timestamp":1792514613903,"version":"4.5.0"},"reference-count":31,"publisher":"Informa UK Limited","issue":"7-8","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"],"published-print":{"date-parts":[[2026,10,2]]},"DOI":"10.1080\/21678421.2026.2667290","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T18:18:03Z","timestamp":1779301083000},"page":"920-930","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Types and frequencies of adverse events across clinical trials for patients with amyotrophic lateral sclerosis: an analysis of the Pooled Resource Open-Access ALS Clinical Trials\u00a0(PRO-ACT) database"],"prefix":"10.1080","volume":"27","author":[{"given":"Sangmi","family":"Kim","sequence":"first","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Curtis","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Iacono","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole F.","family":"Mehdiyoun","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Genge","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, McGill University","place":["Montreal, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander U.","family":"Brandt","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Pooled Resource Open-Access ALS Clinical Trials Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Mancini","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1603471"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14393"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.71"},{"key":"e_1_3_4_5_1","first-page":"Cd001447","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"2012","author":"Miller RG","year":"2012","unstructured":"Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;2012:Cd001447.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30115-1"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204705"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70129-2"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab242"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26801"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-27863-2"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101768"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39147-w"},{"key":"e_1_3_4_14_1","unstructured":"US Food & Drug Administration. Guidance for industry and investigators. Safety reporting requirements for INDs and BA\/BE studies. 2012. Available at: https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM227351.pdf."},{"key":"e_1_3_4_15_1","unstructured":"US Food & Drug Administration. Draft guidance for industry. Safety assessment for IND safety reporting. 2015. Available at: https:\/\/www.fda.gov\/files\/drugs\/published\/Safety-Assessment-for-IND-Safety-Reporting-Guidance-for-Industry.pdf."},{"key":"e_1_3_4_16_1","unstructured":"US Food & Drug Administration. Guidance for industry. Sponsor responsibilities\u2014safety reporting requirements and safety assessment for IND and bioavailability\/bioequivalence studies 2025 Available from: https:\/\/www.fda.gov\/media\/150356\/download."},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000951"},{"key":"e_1_3_4_18_1","unstructured":"PRO-ACT. Pooled resource open-access ALS clinical trials database [Internet] 2025. Available at: https:\/\/ncri1.partners.org\/proact."},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/21678421.2014.964258"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/146608200300079536"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2026.125732"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00242-8"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.2851"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.59058"},{"key":"e_1_3_4_25_1","first-page":"647","article-title":"Pathophysiology, clinical heterogeneity, and therapeutic advances in amyotrophic lateral sclerosis: a comprehensive review of molecular mechanisms, diagnostic challenges, and multidisciplinary management strategies","volume":"15","author":"Gonz\u00e1lez-S\u00e1nchez M","year":"2025","unstructured":"Gonz\u00e1lez-S\u00e1nchez M, Ram\u00edrez-Exp\u00f3sito MJ, Mart\u00ednez-Martos JM. Pathophysiology, clinical heterogeneity, and therapeutic advances in amyotrophic lateral sclerosis: a comprehensive review of molecular mechanisms, diagnostic challenges, and multidisciplinary management strategies. Life (Basel). 2025;15:647.","journal-title":"Life (Basel)"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/17482960802566824"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2024-000829"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-021-10346-9"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-56752-5"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12136"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27244"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2021.2024856"}],"container-title":["Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21678421.2026.2667290","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/21678421.2026.2667290","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21678421.2026.2667290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:07:48Z","timestamp":1792512468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21678421.2026.2667290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":31,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2026,10,2]]}},"alternative-id":["10.1080\/21678421.2026.2667290"],"URL":"https:\/\/doi.org\/10.1080\/21678421.2026.2667290","relation":{},"ISSN":["2167-8421","2167-9223"],"issn-type":[{"value":"2167-8421","type":"print"},{"value":"2167-9223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iafd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iafd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}